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Validation of a chloroquine-induced cell death
mechanism for clinical use against malaria
J-H Ch’ng*,1,2, Y-Q Lee1,3,10, SY Gun4,10, W-N Chia4,10, Z-W Chang4,10, L-K Wong5, KT Batty6,7, B Russell1, F Nosten8,9,
L Renia4 and KS-W Tan1
An alternative antimalarial pathway of an ‘outdated’ drug, chloroquine (CQ), may facilitate its return to the shrinking list of
effective antimalarials. Conventionally, CQ is believed to interfere with hemozoin formation at nanomolar concentrations, but
resistant parasites are able to efflux this drug from the digestive vacuole (DV). However, we show that the DV membrane of both
resistant and sensitive laboratory and field parasites is compromised after exposure to micromolar concentrations of CQ,
leading to an extrusion of DV proteases. Furthermore, only a short period of exposure is required to compromise the viability of
late-stage parasites. To study the feasibility of this strategy, mice malaria models were used to demonstrate that high doses of
CQ also triggered DV permeabilization in vivo and reduced reinvasion efficiency. We suggest that a time-release oral formulation
of CQ may sustain elevated blood CQ levels sufficiently to clear even CQ-resistant parasites.
Cell Death and Disease (2014) 5, e1305; doi:10.1038/cddis.2014.265; published online 26 June 2014
Along with improvements in vector control, surveillance/
diagnosis and treatment accessibility, the development of
new drugs to counteract the problem of drug resistance
remains integral to the eradication agenda.1 Efforts to develop
novel antimalarials have been promising,2,3 and drugs
designed specifically to reverse drug resistance are also
being uncovered.4 However, novel chemical entities are
expensive to test and take considerable time before they
can be deployed. In comparison, alternative strategies to fully
exploit the existing arsenal of antimalarials (largely already
affordable and accessible) are likely to be relatively expedient
and cost-effective.
We had previously demonstrated the existence of a novel
parasite programmed cell death (PCD) mechanism that was
induced by high concentrations of chloroquine (CQ) and
shown that clan CA cysteine proteases were key mediators of
the pathway.5 We had also observed that the permeabilization
of the parasite digestive vacuole (DV) was an important
upstream trigger of this pathway and that other lysosomo-
tropic compounds that are not parasite-specific could similarly
destabilize the DV to initiate parasite PCD.6 We hypothesize
that by altering the dosing regimen or formulation of CQ, it
might be possible to reinstate CQ into antimalarial chemo-
therapy by making use of this novel mechanism.7
In this present study, we begin by showing evidence that
CQ treatment is able to result in the extrusion of DV
proteases into the parasite cytoplasm. Second, we validate
the existence of this PCD pathway in multiple laboratory
strains and field isolates to suggest its clinical relevance and
universality. Third, we investigate the minimum concentra-
tion and duration required for CQ to trigger PCD to determine
if the pharmacokinetics of the current CQ regimen might be
suitable for initiating PCD. Finally, we make use of two
murine malaria models to demonstrate that a short exposure
to high levels of CQ is able to induce parasite DV
permeabilization in vivo and that this procedure reduces
parasite viability.
Results
Extrusion of plasmepsin IV (Plm-IV) from DV after CQ
treatment. To directly link DV permeabilization with the PCD
pathway, we began by investigating whether DV proteases
were released in response to CQ treatment. We used
antibodies to Plm-IV and observed that Plm-IV co-localized
clearly with the hemozoin-containing DV in untreated
parasites (Figure 1a). In 3D7 trophozoites treated with 3 mM
of CQ for 4 h, Plm-IV re-localized from the DV to the parasite
cytoplasm (Figure 1b). The proportion of cells showing DV
localization of Plm-IV decreased markedly from 98 to 21%,
whereas those with cytoplasmic distribution of Plm-IV
increased from 1 to 73% (Figures 1c and d), suggesting that
the DV is the likely reservoir of proteases mediating this PCD
pathway.
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Validation of PCD pathway in multiple laboratory and
field parasites. To investigate the clinical relevance of this
PCD pathway, six laboratory strains (CQ-sensitive: 3D7 and
HB3, CQ-resistant: K1, CS2, Dd2 and T9/94) and six field
isolates were assayed (all CQR, artemisinin delayed-clear-
ance: SMRU0233 and SMRU0272). All tested parasites
show a significant increase in the proportion of parasites
exhibiting these PCD features (all Po0.05) at higher
concentrations of CQ. However, the extent of features varied
between strains and the dose at which these changes were
observed differed between strains/isolates (Figures 2a–d).
Interestingly, no correlation was observed between the CQ
IC50 and the concentration at which PCD features became
evident. The reduced levels of DNA degradation in 3D7 (half
of what was reported previously)5 could be due to in sub-
optimal assaying conditions when working with 12 parasite
lines.
CQ-pulse assays for 3D7. To investigate the combined
effect of CQ concentration and duration of exposure, we
performed a drug-pulse experiment where parasites were
incubated with the stated concentrations of CQ for various
periods before the drug was washed off. Further time was
provided for PCD features to manifest or for reinvasion to
occur.
Treatment of 3D7 with CQ concentrations of 50 and 100 nM
had no measurable effect on JC-1 and Hoechst staining
regardless of treatment duration (Figures 2e and f) and did not
interfere with reinvasion (Figure 2g). Between 500 nM to 2 mM
of CQ, parasites showed a dose- and duration-dependent loss
of JC-1 red staining (Figure 2e). Interestingly, DNA degrada-
tion, measured by sub-G1 Hoechst staining, appeared to
depend more on CQ concentration than exposure period
(Figure 2f). Reinvasion was also clearly inhibited at 500 nM
treatment even with only 1-h exposure (Figure 2g) though
complete inhibition only occurred beyond 4 h. At CQ con-
centrations of 3mM and beyond, the effects of CQ concentra-
tion on JC-1, Hoechst staining and reinvasion was maximal
even after only 1-h exposure. Schizont maturation was also
not observed.
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Figure 1 Plm-IV localization assay. (a) Confocal microscopy images show that Plm-IV co-localizes with the dark hemozoin-containing DV in healthy 3D7 P. falciparum
parasites but not in (b) parasites treated with 3 mM of CQ for 4 h, where Plm-IV staining is less intense and is found throughout the parasite cytoplasm. (Scale bar set at 5mm).
(c) The number of parasites counted and respective percentages, with and without CQ-treatment, and as represented in (d) histogram form, shows a clear redistribution of
Plm-IV out of the DV into the cytoplasm
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Ex vivo DV permeabilization of CQ-treated P. berghei
and P. yoelii parasites. To test the possibility of using
murine malaria models, P. berghei and P. yoelii susceptibility
to DV permeabilization was assayed using infected blood
from hyperparasitemic mice (above 20% parasitemia). Four
hours after freshly drawn blood was spiked with 3 mM of CQ
or PBS, cells were stained with Fluo-4AM to determine
whether Ca2þ had redistributed out of the DV. Due to
difficulties in identifying parasite-infected erythrocytes and
visualizing the DV, only late-stage parasites with multiple
nuclei and prominent DV were captured.
About 90 and 80% of healthy P. berghei and P. yoelii
parasites, respectively, showed clear Fluo-4-AM staining of
the hemozoin-containing DV (Figures 3a–c), which for
simplicity will be termed as Fluo4AM-positive parasites. In
the CQ-treated cells, this proportion were reduced to 60 and
40%, respectively, showing that DV permeabilization also
occurs in P. berghei and P. yoelii parasites after CQ
treatment.
Viability assay of CQ-treated P. berghei and P. yoelii
parasites. Due to difficulty in performing PCD assays
JC1 Assay for Lab Strains
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Hoechst-loss Assay for Lab Strains
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Figure 2 JC-1, Hoechst and reinvasion assays. (a) JC-1 loss occurs in both lab strains and (b) field isolates after 10 h of high-dose CQ treatment. (c) Similarly, both lab
strains and (d) field isolates show signs of DNA degradation as indicated by the reduction of Hoechst staining. *P-values o0.05 for all points at 7500 nM (boxed) when
compared with untreated, with point-specific P-values are provided in Supplementary Figure S1. 3D7 parasites were exposed to various doses of CQ for various durations
before the drug was washed off and the parasites left to incubate further. After a total of 10 h, (e) JC-1- and (f) Hoechst-stained parasites were measured while (g) reinvasion
efficiency was only measured after a total of 34 h. (N¼ 3)
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(the presence of leukocytes, gametocytes, asynchronous
infection, multiple infection and infected reticulocytes having
organelles), the viability of CQ-treated schizonts to infect
naive mice were assayed instead.
As P. berghei schizonts do not rupture/reinvade in vitro,
blood from hyperparasitemic mice was matured until they
were primarily schizonts. Parasites were exposed to CQ for
4 h before the drug was washed off and the blood injected into
naive mice. In the untreated controls, parasitemia increased
almost two-fold by 6 h postinfection reaching a stable
parasitemia by 9 h (Figure 4a). A similar trend was also
observed in parasites treated with 30 nM of CQ for 4 h,
suggesting that this level of drug did not interfere with schizont
viability. However, 4 h after 3mM of CQ, parasitemia declined
steadily throughout the first 18 h and remained low throughout
the observed period, indicating that schizont viability was
severely compromised.
Schizont maturation could not be performed with P. yoelii
parasites as their schizonts rupture in vitro. As such, CQ was
added directly to freshly isolated (asynchronous) parasites for
4 h before washing off the drug and infecting naive mice.
Parasitemia of mice infected with untreated parasites showed a
steady increase in parasitemia (Figure 4b) detectable after 6 h
(Po0.05). A similar increase was detected in mice infected with
parasites exposed to 30 nM of CQ for 4 h. In contrast,
parasitemia in mice infected with parasites exposed to 3mM of
CQ only showed a marginal increase in parasitemia after 18 h
(Po0.05). For comparison, an identical experiment with
P. berghei was performed, and a similar trend was observed
with parasites showing a marked reduction in viability after
treatment with 3mM CQ (Figure 4c). Although the mixed-stage
infection makes it difficult to examine the effects of CQ treatment
on any specific parasite stage, the early reduction in parasitemia
fold-change (within 9 h postinfection) suggest that the late-stage
P. yoelii and P. berghei parasites were compromised.
In vivo DV permeabilization of P. berghei and P. yoelii
parasites in CQ-fed mice. To determine whether parasite
Condition
P. berghei + Veh
DV fluorescent DV not fluorescent Total Counts N
P. berghei + 3 µM CQ
P. yoelii + Veh
81 (93.1%) 6 (6.9%) 87 (100%) 3
57 (61.3%) 36 (38.7%) 93 (100%) 3
100 (78.7%) 27 (21.3%)
74 (58.3%)
127 (100%) 3
P. yoelii + 3 µM CQ 53 (41.7%) 127 (100%) 3
iv. P. yoelii (CQ)iii. P. yoelii (NA)




















Effects of CQ on Fluo4AM Staining
DV not fluorescent
DV fluorescent
Figure 3 Fluo-4AM staining of Ca2þ in murine malaria parasites. Infected blood was harvested from balb/c mice 14 days postinfection with either P. berghei or P. yoelii,
and magnetically enriched late stages were treated ex vivo with (ai and iii) vehicle control or (aii and iv) 3 mM of CQ for 4 h before Fluo-4AM staining and viewing by confocal
microscopy. Cells were (b) enumerated and results are presented as (c) histogram format
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DV permeabilization occurs in vivo, parasitized blood was
obtained from mice 4 h after they were fed with various doses
of CQ by oral gavage. Once again, parasitized blood from
infected mice that were stained with Fluo-4AM ex vivo showed a
dose-dependent decrease in the proportion of Fluo4AM-positive
P. berghei and P. yoelii parasites (Figures 5a and b). This
decrease was most significant when mice were fed 50 mg/kg
(Po0.05 for both species), suggesting that a higher dose of
the drug resulted in a more pronounced effect (Figure 5c).
CQ pharmacokinetics in murine model. To correlate the
results from the in vivo and ex vivo studies, we assayed for
whole-blood levels of CQ in drug-treated mice. In uninfected
mice treated with 10, 20 and 50 mg/kg of CQ, blood CQ
concentrations were approximately 1000, 2000 and 5800 nM,
respectively, after 1 h, and decreased to about 800, 700 and
2000 nM, respectively, by 4 h (Figure 6a).
In hyperparasitemic P. berghei-infected mice (between 30
and 60% parasitemia at day 14 postinfection), a more
pronounced accumulation of CQ was detected, reaching
about 4700, 10 640 and 27 700 nM after only 1 h posttreat-
ment with 10, 20 and 50 mg/kg of the drug. After 4 h, blood
concentration was 9300, 12 400 and 23 900 nM, respectively
(Figure 6b). Compared with the uninfected mice, the higher
overall blood CQ concentrations was likely due to the drug’s
accumulation within the parasites.8
In hyperparasitemic P. yoelii-infected mice (between 20 and
40% parasitemia at day 14 postinfection), the increased
accumulation of CQ was similarly noted. One hour after being
given 10, 20 or 50 mg/kg of the drug, blood CQ concentra-
tions reached 5800, 11 400 and 18 800 nM, respectively
(Figure 6c). After 4 h, this level declined to about 5500, 8200
and 14 200 nM, respectively.
To facilitate comparison with other studies on plasma CQ
levels, plasma levels of P. yoelii mice given 10, 20 and
50 mg/kg of CQ were collected after 4 h and contained about
200, 330 and 770 nM, respectively (results not shown). This
corresponded to between 17- and 22-fold reductions from the
corresponding whole-blood levels and indicated that CQ
accumulates more within blood cells relative to plasma.
Pharmacodynamic studies of CQ on parasitemia. To
understand the effects of varying CQ doses on parasite
clearance, parasitemia was monitored in P. berghei- and
P. yoelii-infected mice (Figures 6d and e). Although all tested
doses similarly reduced P. berghei parasitemia 9 h posttreat-
ment (all Po0.05), only 50 mg/kg was able to reduce
parasitemia within 6 h (Po0.05), suggesting that a higher
dose may elicit a more rapid decrease in parasitemia.
By comparison, inhibition of P. yoelii parasitemia appeared
unaffected by CQ treatment until 24 h where only the 20 and
50 mg/kg dose showed an appreciable reduction in para-
sitemia (Po0.05 and Po0.01, respectively), with the latter
having a more pronounced effect.
Discussion
We had previously characterized a novel PCD pathway in
P. falciparum that is mediated by clan CA cysteine proteases
and suggested that these proteases may originate from the
parasite DV.5 We also demonstrated that fluorescent-labeled
CQ as well as Ca2þ was able to re-distribute out of the DV in a
rapid and abrupt manner and provided ultrastructural
evidence of membrane breaching.6 In this study, we show
that high concentrations of CQ result in the extrusion of Plm-IV
out of the DV into the cytoplasm of the parasite, which is in
contrast to the classical antimalarial mechanism of CQ
involving the inhibition of hemozoin polymerization and the
gradual buildup of toxic by-products.9 Plm-IV is a 51-kDa
aspartic protease that localizes to the parasite DV and is
involved in hemoglobin hydrolysis.10,11 It appears plausible
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Figure 4 Schizont reinvasion assay. (a) Parasitemia of mice infected with
P. berghei schizonts matured ex vivo or mixed stages of (b) P. yoelii and (c) P. berghei
treated ex vivo with 30 nM or 3000 nM of CQ for 4 h. *P-values o0.05 or **P-values
o0.01 for points (boxed) when compared with respective no-drug control at the same
time point. Point-specific P-values are provided in Supplementary Figure S2
Validation of alternative mechanism of CQ
J-H Ch’ng et al
5
Cell Death and Disease
such as the falcipains (55.8–56.7 kDa), could likewise be
extruded from the DV to execute PCD.
In addition to the three laboratory strains previously
characterized,5 the four additional laboratory strains (one
CQS and three CQR parasites) and six field isolates from
Thailand (all CQR, including two artemisinin-‘resistant’
delayed-clearance parasites) all exhibited some level of PCD
hallmarks, albeit at varying micromolar concentrations,
suggesting that this pathway is well conserved in P. falciparum
and is therapeutically relevant. Though the extent of DNA
degradation between strains and isolates tended to vary, this
could be due to limitations in simultaneously assaying 12
parasite lines – parasites had varying life-cycle durations and
consequently differed in staging at the commencement of
experiments. In comparison, the extent of mitochondrial
dysregulation was consistent between parasite lines, probably
owing to the greater sensitivity of the assay. Heterogeneity in
PCD profiles between strains has been previously discussed5
and remains the subject of future investigations.
As micromolar concentrations of CQ are only transient
in vivo,12 we investigated whether transient high concentra-
tions of CQ were sufficient to trigger parasite PCD and inhibit
reinvasion using a drug-pulse assay. Interestingly, micro-
molar levels of CQ were able to trigger parasite PCD features
and inhibit reinvasion even with only 1-h exposure, whereas
nanomolar concentrations did not, even after 10-h exposure.
This difference suggests that the ‘classical’ antimalarial
mechanism of CQ that is effected at near IC50 levels (inhibition
of hemozoin polymerization13) differs from the mechanism of
CQ at micromolar concentrations, which is likely to be more
rapidly injurious. Another study on the stage-dependent
sensitivity of P. falciparum to CQ showed similar results,
where trophozoites and schizonts exposed to 1mM CQ for 2 h
had reinvasion inhibited by 60% and inhibition was complete
after 4-h exposure.14
To develop an in vivo assay, P. berghei and P. yoelii
parasites were first treated with micromolar CQ ex vivo, and a
reduction in the proportion of Fluo-4AM-positive parasites was
observed. Interestingly, late stages of both P. berghei and
P. yoelii parasites showed similar changes even though P. yoelii
is known to exhibit innate resistance to CQ.15 Furthermore,
there was a dramatic reduction parasite reinvasion, which was
very apparent in P. berghei (assay performed with schizont-
synchronized inoculums) but also detectable in P. yoelii
(by focusing on the initial reduction of reinvasion). In contrast,
nanomolar CQ exposure showed no effect and suggests that
this low level of drug did not have any rapid-onset effect on
reinvasion. The association between DV permeabilization and
reduced reinvasion in mice malaria parasites is consistent with
findings from the P. falciparum experiments and suggests that a
similar PCD pathway may be involved.
The effects of CQ dosing in vivo was then tested, and mice
treated with 50 mg/kg CQ showed a significantly larger
proportion of P. berghei and P. yoelii parasites with
compromised DV compared with mice that received lower
doses. Alterations to the DV membrane in response to
escalating doses of CQ has previously been demonstrated
in P. berghei in conditions similar to our study, suggesting that
high doses of CQ triggers DV dysfunction in vivo.16,17
In an attempt to link in vitro, ex vivo and in vivo results, blood
CQ concentrations were assayed in CQ-fed mice. In both
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Figure 5 Fluo-4AM staining after CQ administration to infected mice. Mice infected with P. berghei or P. yoelii were fed with various doses of CQ, and blood was harvested
after 4 h. After magnetic enrichment for late stages, cells were stained with Fluo-4AM, visualized by confocal microscopy and enumerated. After three experiments, (a) the
pooled counts are displayed (b) in histogram. Taking the mean percentage from each experiment, (c) the mean and S.E.M. are shown here. (*Po0.05, NZ4)
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blood levels remained at approximately 5mM for at least 3 h.
This value was five-fold more than the corresponding value in
uninfected mice, suggesting that a significant amount of CQ
detected may have come from within parasitized erythrocytes.
Although whole-blood sampling is generally considered a
more accurate measure in clinical pharmacokinetic studies of
CQ,12,18,19 serum/plasma CQ concentrations may be more
indicative of cell/tissue exposure levels and prove more
meaningful in linking in vitro and in vivo findings. Whole-blood
CQ levels, at least in mice malaria models, could be affected
by differences in hematocrit and parasitemia, both of which
can vary significantly depending on parasite species, initial
inoculum load and day postinfection. One study showed that
blood CQ concentrations in humans were between 5 and
10-fold higher than in serum,12 and another study demonstrated
that blood CQ concentrations in P. chabaudi-infected mice
with a heavy infection could be 4- to 5-fold higher than mice
with light infection.20 Taken together, it might be deduced that
whole-blood CQ levels could be between 20 and 50 times
those of the plasma levels, and indeed, our own assays on a
limited number of plasma samples show a blood-to-plasma
ratio of about 20 : 1.
Using this estimate, the plasma CQ levels may be
approximated to be around 1mM in both P. berghei and
P. yoelii mice after a single 50 mg/kg dose, a concentration
sufficient to trigger DV permeabilization in vitro. This closely
resembles the results from yet another study on P. berghei-
infected mice (light infection of 3–4%) where plasma levels of
CQ after a single 50 mg/kg intraperitoneal injection was
between 500 and 1000mg/l (approximately, 1.5–3 mM) during
the initial 4-h postadministration.21 By the same ratio, plasma
CQ levels would be about 200–620 nM after a 10–20 mg/kg
dose, respectively—concentrations insufficient to trigger DV
permeabilization in vitro.
To determine whether the decrease in parasites with
functional DV corresponded to a decrease in parasite viability,
parasitemia was tracked throughout the day in mice treated
with 10, 20 or 50 mg/kg of CQ. During the first 6 h following 10
and 20 mg/kg of CQ, the increase in P. berghei parasitemia
suggested that late-stage parasites were still viable and
managed to reinvade. Only 9 h following the drug administra-
tion was there a clear reduction in parasitemia. With 50 mg/kg
of CQ, there was negligible increase in parasitemia during the
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Figure 6 CQ pharmacokinetics and pharmacodynamics. The whole-blood concentration of CQ in (a) uninfected, (b) P. berghei-infected and (c) P. yoelii-infected mice fed
with 10, 20 or 50 mg/kg of CQ at 1 or 4 h postadministration. *Po0.05 or **Po0.01 when compared with 10 mg/kg mice at the same time point, with point-specific P-values
provided in Supplementary Figure S3. Parasitemia change of mice infected with (d) P. berghei or (e) P. yoelii after a single oral dose of 10, 20 or 50 mg/kg of CQ. *Po0.05 or
**Po0.01 when compared with no-drug control mice at the same time point, with point-specific P-values provided in Supplementary Figure S4
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suggesting that late-stage parasites showed reduced reinva-
sion propensity at higher blood CQ concentrations. Though
the inherent resistance of P. yoelii parasites to CQ has been
described,15 it is possible that parasites in the present study
were inhibited at 50mg/kg due to DV permeabilization and
associated PCD.
Although dosage escalation is possible in rodent models,
the low therapeutic index of CQ means that increasing CQ
dosage recommendations need to be cautiously considered.
We suggest that a slow-release CQ formulation may permit a
gradual increase in blood CQ concentration and sustain
these levels sufficiently to trigger parasite PCD while
minimizing the risk of toxicity associated with the transient
distribution-phase spike in concentration.7 A study by White
et al.22 using a continuous CQ infusion of 25 mg/kg at a rate
of 0.83 mg/kg/h has shown evidence that whole-blood CQ
levels could be maintained beyond 1000 mg/l (B3 mM) for
over 10 h (between 20 and 30 h posttreatment) without
increased side effects. Other studies suggest that smaller
repeated oral doses may also achieve a higher blood
concentration and increasing drug efficacy without increas-
ing Cmax.
23–25 Only in concert with comprehensive pharma-
cokinetic and pharmacodynamic studies will it be possible to
achieve a dosing regimen or drug formulation that will truly
maximize the therapeutic effectiveness of CQ and other
antimalarials.26
Though this approach to exploit the ‘unconventional’
antimalarial activity of CQ shows some early promise, it will
need to be given in combination with other drugs to prevent
the emergence of resistant parasites. In such a context, CQ
may once again find its place in the shrinking arsenal of
effective antimalarial drugs if we are able to exploit its
alternative antimalarial mechanism of action that can circum-
vent the current mechanism of drug resistance.
Materials and Methods
Parasite culture and CQ treatment. Six laboratory strains of
P. falciparum, 3D7 (MRA-102), HB3 (MRA-155), K1 (MRA-159), CS2 (MRA-96),
Dd2 (MRA-156) and T9/94 (MRA-153), were obtained from MR4, ATCC,
Manassas, VA, USA. Six P. falciparum field isolates were collected from malaria
patients attending the clinics of the Shoklo Malaria Research Unit (SMRU) Mae
Sod region of Tak Province in the Northwest of Thailand from January 2009 to
December 2010 and designated as SMRU0233, SMRU0270, SMRU0272,
SMRU0279, SMRU1093 and SMRU1116. P. falciparum culture and CQ
preparation were described previously.5
Immunofluorescence microscopy for Plm-IV. Thin blood smears of
untreated and CQ-induced cultures (3 mM, 4 h) were fixed in acetone–methanol
(7 : 3), permeabilized with 0.1% Triton-X for 10 min and blocked in 3% BSA.
Mouse monoclonal anti-Plm-IV antibody (1 : 10 dilution in 3% BSA) (MRA-814A,
MR4, ATCC) was added for 1 h, and slides were washed three times before
incubation with Cy3 goat anti-mouse IgG (Hþ L) secondary antibody (1 : 1000
dilution, Molecular Probes, Eugene, OR, USA) with Hoechst 33342 (0.8mg/ml). At
least 250 parasitized erythrocytes were examined by confocal microscopy over
three experiments.
Co-staining with JC-1 and Hoechst for laboratory and field
parasites. Parasite staining was with JC-1 (Molecular Probes) and Hoechst
33342 (Invitrogen, Eugene, OR, USA) and analysis has been described.6
CQ-pulse assay. Trophozoite cultures were incubated with CQ for varying
durations before cells were washed twice with MCM and returned to culture.
Inclusive of CQ treatment time, cells were incubated for a total of 10 h to assay for
PCD features or 34 h for reinvasion.
Mice, parasites, experimental infections and drug treatment. Six
to twelve weeks old BALB/c mice were bred under specific pathogen-free
conditions in the Biomedical Resource Centre, Singapore, Singapore. P. berghei
ANKA (clone 15Cy1) and P. yoelii yoelii (17X clone 1.1) parasites were maintained by
passage through naive mice. Experimental infections were initiated by intraperitoneal
injection of 106 infected red blood cells from stabilates prepared by passage in C57BL/
6J mice and stored in liquid nitrogen in Alsever’s solution. Parasitemia was monitored
by flow cytometry27 and/or Giemsa-staining. Blood was drawn by cardiac puncture
from mice killed by asphyxiation, collected in a heparinized Vacutainer (BD, Franklin
Lakes, NJ, USA) and used immediately after being washed once in 10 ml PBS.
Alternatively, smaller quantities of blood (B100ml) were obtained via facial bleeding.
Administration of CQ was via oral gavage.
Fluo-4AM staining of murine parasites. In ex vivo studies, blood was
resuspended to 25% hematocrit in MCM and then spiked with various
concentrations of CQ for 4 h at 37 1C. Mature parasites were enriched using
magnetic column method28 and stained with the Fluo-4-AM as previously
described for P. falciparum.6 For in vivo studies, CQ-fed mice were left for 4 h
before blood was harvested, enriched and stained.
Schizont maturation assay and infection of naive mice. Blood was
resuspended in schizont maturation media29 supplemented with 20% FBS for 8 h
at 0.2% hematocrit. Thereafter, 30 nM or 3mM of CQ was added for a further 4 h.
Cells were washed three times with 50 ml of PBS, and naive mice were then
infected by intravenous retro-orbital injection of 0.1 ml of packed cells. For the
experiments without schizont maturation, infected blood was resuspended to 2%
hematocrit in MCM, spiked with CQ for 4 h, washed twice with 30 ml PBS and
injected. Parasitemia was tracked by FACS as before.27
LC–MS sample preparation and separation parameters. Blood
from infected and uninfected mice was collected and stored at  80 1C. For
plasma collection, whole blood (B700ml) was centrifuged at 900 g for 10 min,
and 200ml of supernatant was aspirated. Standards were prepared by spiking
blood/plasma of infected and uninfected mice with CQ to a final concentration of
30, 150, 300, 1500 and 3000 nM. Chromatographic separation was carried out
using a RSLC system (Dionex, Germering, Germany) with a Poroshell 300SB-C8
2.1 75 mm2, 5-mm column (Agilent, Santa Rosa, CA, USA) at a flow rate of
0.2 ml/min with 0.5% acetic acid and acetonitrile as solvents. MS detection utilized
micrOTOF-QII mass spectrometer (Bruker, Bremen, Germany). CQ was eluted at
approximately 1.2 min. Chromatogram of CQ, 320.18 m/z, was extracted and
integrated for all blood/plasma standards (30, 150, 300, 1500 and 3000 nM) using
the DataAnalysis 4.0 software (Bruker).
Flow cytometry. Cell numbers and fluorescence intensity was assayed using
either the BD LSRII Special Order System (BD, San Jose, CA, USA) or CyAn ADP
(Beckman Coulter, Fort Collins, CO, USA) as described previously,6 and a
minimum of 100 000 erythrocytes were analyzed.
Statistics. All data shown are mean±S.E.M. Statistical difference was
analyzed using ANOVA and post-hoc comparison using Tukey’s test. For mice
experiments, the Kruskall–Wallis test was used. Significantly different results
(Pr0.05) were highlighted.
Ethics. Blood collection for malaria culture was approved by Institutional
Review Board (IRB) of the National University of Singapore (NUS-IRB Reference
Code: 11–383, Approval Number: NUS-1475). Clinical field isolates were
collected following ethical guidelines in approved protocols: OXTREC Reference
Number 29-09 (Center for Clinical Vaccinology and Tropical Medicine, University
of Oxford, Oxford, UK). Use of field isolates was in accordance with NUS IRB
(Reference Code: 12-369E). All animal experiments and procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) of
A*STAR (Biopolis, Singapore) (Authorization No. IACUC no.110630) in
accordance with the guidelines of the Agri-Food and Veterinary Authority
(AVA) and the National Advisory Committee for Laboratory Animal Research
(NACLAR) of Singapore.
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